Compare ASTI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | GLMD |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.6M |
| IPO Year | N/A | 2014 |
| Metric | ASTI | GLMD |
|---|---|---|
| Price | $4.07 | $0.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 146.8K |
| Earning Date | 11-10-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,134.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.85 | N/A |
| 52 Week Low | $1.10 | $0.73 |
| 52 Week High | $7.40 | $3.61 |
| Indicator | ASTI | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 32.44 |
| Support Level | $3.07 | $0.75 |
| Resistance Level | $5.30 | $1.00 |
| Average True Range (ATR) | 1.29 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 31.24 | 9.86 |
Ascent Solar Technologies Inc is engaged in the manufacturing, and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.